Merck, Inc.
🇵🇭Philippines
Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)
Phase 3
Terminated
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 56
- Registration Number
- NCT00423800
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
Phase 2
Terminated
- Conditions
- Carcinoma, Non-Small-Cell LungEsophageal NeoplasmColorectal NeoplasmHead and Neck Neoplasm
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 86
- Registration Number
- NCT00423150
Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)
Phase 2
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: boceprevir (SCH 503034)Drug: peginterferon-alfa 2b (PegIntron)Drug: ribavirinDrug: ribavirin (low-dose)
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 765
- Registration Number
- NCT00423670
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
Phase 1
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 61
- Registration Number
- NCT00423449
Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)
Phase 3
Completed
- Conditions
- Anesthesia
- Interventions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 94
- Registration Number
- NCT00421148
The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)
Phase 2
Completed
- Conditions
- Atherosclerosis
- Interventions
- Drug: MK0633
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 180
- Registration Number
- NCT00421278
Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00420680
A Weight Maintenance Study in Obese Patients (0364-012)(TERMINATED)
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2015-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT00420589
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: MK0249
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 144
- Registration Number
- NCT00420420
Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)
- Conditions
- Lymphoma, T-Cell, Cutaneous
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00419367
© Copyright 2025. All Rights Reserved by MedPath